Argus Research Downgrades Silk Road Medical to Sell
Argus Research analyst Steve Silver downgrades Silk Road Medical (NASDAQ:SILK) from Buy to Sell.
Cathie Wood Touts Palantir, Coinbase And Roku As ARK's Flagship Fund Shifts Focus From Mag 6 Amid 'Whiff' Of Lower Interest Rates
In a recent letter to investors, Cathie Wood, the CEO of ARK Invest, highlighted the potential of the company's flagship fund, ARK Innovation ETF (NYSE:ARKK), despite its recent underperformance.
Baird Maintains Outperform on Longboard Pharmaceuticals, Raises Price Target to $60
Baird analyst Joel Beatty maintains Longboard Pharmaceuticals (NASDAQ:LBPH) with a Outperform and raises the price target from $36 to $60.
Longboard Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/11/2024 62.12% Baird $36 → $60 Maintains Outperform 07/02/2024 21.59% Citigroup $40 → $45 Maintains
Absci Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/11/2024 66.67% Keybanc $8 → $6 Maintains Overweight 07/03/2024 94.44% Morgan Stanley → $7 Initiates
Alight Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/11/2024 43.68% Keybanc $11 → $10 Maintains Overweight 07/01/2024 58.05% Needham $11 → $11 Reiterates
Delta Leads the Airline Sector Lower After Warning of Lower Fare Discounting
LifeMD Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/11/2024 71.82% Keybanc $12 → $10 Maintains Overweight 06/05/2024 106.19% Keybanc → $12 Initiates
Wall Street Jittery Ahead Of Key Inflation Data After Delta Air Lines, Pepsi Disappoint: Strategist Recommends Sector Picks Amid Evolving Election Dynamics
The futures market on Thursday reflected jitteriness as traders awaited the all-important consumer price inflation data. The broader market is amid a multi-session winning run and has been breaking
Phreesia Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/11/2024 32.84% Keybanc $27 → $25 Maintains Overweight 07/01/2024 54.09% Truist Securities $29 → $29
Recursion Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/11/2024 65.52% Keybanc $16 → $12 Maintains Overweight 06/25/2024 134.48% Needham $17 → $17 Reiterates
Schrodinger Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/11/2024 21.48% Keybanc $30 → $25 Maintains Overweight 07/02/2024 40.91% Leerink Partners → $29
Itron Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/11/2024 27.45% Guggenheim → $130 Upgrades Neutral → Buy 06/20/2024 17.65% Canaccord Genuity $115 → $120
Biden Administration to Award $1.7B in Grants to Boost Domestic EV Production
KalVista Submits FDA Application for Sebetralstat; Phase 3 Trial Results Published
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today provided an operational update and released financial results for the fiscal year ended April 30, 2024."This last fiscal quarter was the most
Instructure Hldgs Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/11/2024 30.67% Needham $32 → $32 Reiterates Buy → Buy 05/17/2024 30.67% Needham $32 → $32 Reiterates
Core Scientific Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/11/2024 50% HC Wainwright & Co. $15 → $15 Reiterates Buy → Buy 07/10/2024 50% HC Wainwright & Co. $11 →
Akebia And CSL Vifor Have Terminated The License Agreement Providing For The Payment Of Royalties By Akebia To CSL Vifor On Vafseo (Vadadustat) U.S. Net Product Sales. As A Result, Akebia Regained Full Rights To Sell Vafseo In The U.S.
Under the terms of the agreement, CSL Vifor is entitled to quarterly tiered royalty payments ranging from a high single-digit percentage on annual net sales up to $450 million to a mid-single digit
The largest producer country imposes taxes, and uranium mining stocks rose sharply overnight!
After Kazakhstan, the world's largest uranium producer, unexpectedly increased mining taxes, uranium mining stock prices soared.
Revolutionary changes in lithium mining? IBAT has achieved commercialization of new lithium extraction technology for the first time.
The metal that is crucial for energy transition—lithium, has had a major breakthrough in mining technology. With the direct lithium extraction (DLE) technique, lithium production capacity is expected to double compared to current levels.